Voretigene neparvovec clinical trials
Also written AAV2-hRPE65v2.
How each study uses voretigene neparvovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 19 Dec 2017 · Luxturna · BLA 125610 (FDA, Purple Book)
- European Union
- 22 Nov 2018 · Luxturna · EMEA/H/C/004451 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test voretigene neparvovec.
- Oct 2027Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Phase 1/2 · Spark Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses voretigene neparvovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Active, not recruitingPhase 1/2Spark Therapeutics, Inc.NCT01208389Written as voretigene neparvovec-rzyl
- Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisActive, not recruitingPhase 3Spark Therapeutics, Inc.NCT00999609Written as AAV2-hRPE65v2,voretigene neparvovec-rzyl
- Safety Study in Subjects With Leber Congenital AmaurosisCompletedPhase 1Spark Therapeutics, Inc.NCT00516477Written as voretigene neparvovec-rzyl
Codes
What other systems call voretigene neparvovec · ClinicalTrials.gg INT014525
- UNII (FDA) 2SPI046IKDVORETIGENE NEPARVOVECConfirmed FDA, Wikidata
- RxNorm 1995537Confirmed FDA, Wikidata
- Wikidata Q48988385voretigene neparvovecConfirmed FDA, Wikidata
- NCI Thesaurus C152915Voretigene NeparvovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2SPI046IKD | VORETIGENE NEPARVOVEC | Confirmed FDA, Wikidata |
| RxNorm | 1995537 | — | Confirmed FDA, Wikidata |
| Wikidata | Q48988385 | voretigene neparvovec | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152915 | Voretigene Neparvovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.